medmix appoints new CEO

Ad hoc announcement pursuant to Art. 53 LR

April 10, 2024

 

medmix appoints René Willi as new Chief Executive Officer

medmix announces the appointment of René Willi as its new CEO, effective June 1, 2024.
Current CEO Girts Cimermans will be stepping down as of today.

René Willi was unanimously elected by the Board of medmix as new CEO, effective June 1, 2024. René, a Swiss citizen, has been CEO of the Global Oral Reconstruction Group of Henry Schein and a member of its Executive Management Committee since 2021. Before joining Henry Schein, a US-based global healthcare company, he served as Head of the Surgical business unit at the Swiss oral care company Straumann. He started his career as a consultant with McKinsey & Company. René Willi holds a PhD in Technical Sciences from ETH Zürich. He has served as a member of the Board of Directors of medmix since 2022 and will continue to do so until further notice, if re-elected at the upcoming Annual General Meeting.

Rob ten Hoedt, Chairman of the Board of Directors, stated: "The Board of Directors is delighted to appoint René to his new position. Thanks to the variety of roles that he has held, René is familiar with our business, in particular in the healthcare industry, and he has gained a global insight into our core markets, the USA, Europe and Asia. As René has been serving as a member of the Board of medmix, he already has in-depth knowledge of our company. This will ensure a rapid onboarding and seamless transition in dialogue with our customers, shareholders, business partners, and our employees.”

René Willi commented: “I am excited and honored to be appointed as CEO of our company. With the IPO in 2021, medmix has developed a powerful and successful strategy, and on this basis, we now will move into the future together. Our focus will be on creating value for our customers and our shareholders by achieving sustained profitable growth and improving the way we run the company. I look forward to getting to know the different parts of our organization more, and to working with the dedicated and highly qualified teams worldwide.”

Rob ten Hoedt further declared: “On behalf of the Board, I would like to thank Girts Cimermans for his instrumental role in establishing medmix as a stand-alone listed company, for his unwavering dedication and commitment to medmix customers and employees. Moreover, we are grateful for his leadership in a dynamic business environment. We wish him all the best in his future endeavors."

 

About medmix

medmix is a global leader in high-precision delivery devices, with leading positions in healthcare, consumer and industrial end-markets. Our customers benefit from our dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2’700 employees are at service of our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss

 

Inquiries:

Investor Relations: investorrelations@medmix.com

Media Relations: communications@medmix.com

 

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.